Workflow
NewAmsterdam Pharma Company (NasdaqGM:NAMS) 2026 Conference Transcript
2026-03-09 13:42
NewAmsterdam Pharma Company (NasdaqGM:NAMS) 2026 Conference March 09, 2026 08:40 AM ET Company ParticipantsIan Somaiya - CFOMichael Davidson - CEOConference Call ParticipantsRoanna Ruiz - Senior Biotech AnalystRoanna RuizOkay, great. I think we're at time, I'll kick it off. Hey, everybody. I'm Roanna Ruiz, one of the Senior Biotech Analysts here at Leerink Partners. Just wanna welcome everybody to our global healthcare conference, it's my pleasure to introduce NewAmsterdam Pharma. I've got the CEO, Michael ...
Spyre Therapeutics (NasdaqGS:SYRE) 2026 Conference Transcript
2026-03-09 13:42
Spyre Therapeutics (NasdaqGS:SYRE) 2026 Conference March 09, 2026 08:40 AM ET Company ParticipantsCameron Turtle - CEOSheldon Sloan - Chief Medical OfficerConference Call ParticipantsTom Smith - Senior Managing Director and Senior Biotechnology AnalystTom SmithGood morning, everyone. Thanks for joining us here at the Leerink Partners Global Healthcare Conference. My name's Tom Smith. I'm one of the senior biotech analysts here at Leerink, and it's my pleasure to introduce our next company, Spyre Therapeutic ...
Neurocrine Biosciences (NasdaqGS:NBIX) 2026 Conference Transcript
2026-03-09 13:40
Neurocrine Biosciences (NasdaqGS:NBIX) 2026 Conference March 09, 2026 08:40 AM ET Speaker0Thanks for joining us. I'm Marc Goodman, one of the biopharma analysts at Leerink, and it's great to have Neurocrine here. We have Matt Abernathy, who's the CFO, and Todd Tushla, who's the IR guy. Thank you very much for joining us. Matt, I'll give you a chance just to make an opening comment, maybe not too long, but, you know, just kind of set the stage.Speaker1I'll try to run out the clock.Speaker0YeahSpeaker1if that ...
Neurocrine Biosciences (NasdaqGS:NBIX) 2026 Conference Transcript
2026-03-09 13:40
Neurocrine Biosciences (NasdaqGS:NBIX) 2026 Conference March 09, 2026 08:40 AM ET Speaker0Thanks for joining us. I'm Marc Goodman, one of the biopharma analysts at Leerink Partners, and it's great to have Neurocrine here. We have Matt Abernethy, who's the CFO, and Todd Tushla, who's the IR guy. Thank you very much for joining us. Matt, I'll give you a chance just to make an opening comment, maybe not too long, but, you know, just kind of set the stage.Speaker1I'll try to run out the clock if that's okay.Spe ...
3D Systems(DDD) - 2025 Q4 - Earnings Call Transcript
2026-03-09 13:32
3D Systems (NYSE:DDD) Q4 2025 Earnings call March 09, 2026 08:30 AM ET Company ParticipantsJeff Graves - President and CEOMonica Gould - Vice President of Investor RelationsPhyllis Nordstrom - Interim CFO, Executive Vice President, and Chief Administrative OfficerConference Call ParticipantsGreg Palm - Senior Research AnalystJim Ricchiuti - Managing Director, Senior Equity Research AnalystKieran McCabe - Vice President, Equity Research AnalystOperatorWelcome to the 3D Systems fourth quarter and full year 20 ...
ARS Pharmaceuticals(SPRY) - 2025 Q4 - Earnings Call Transcript
2026-03-09 13:32
ARS Pharmaceuticals (NasdaqGM:SPRY) Q4 2025 Earnings call March 09, 2026 08:30 AM ET Company ParticipantsEric Karas - Chief Commercial OfficerJustin Chakma - Chief Business OfficerKathy Scott - CFOKevin Holder - Equity Research AssociateRichard Lowenthal - Co-Founder, President, and CEOConference Call ParticipantsAndreas Argyrides - Managing Director and Senior Biotech AnalystLachlan Hanbury-Brown - Biotech Equity Research AnalystNone - AnalystOperatorGood morning and welcome to ARS Pharmaceuticals' fourth ...
Unusual Machines(UMAC) - 2025 Q4 - Earnings Call Transcript
2026-03-09 13:32
Unusual Machines (NYSEAM:UMAC) Q4 2025 Earnings call March 09, 2026 08:30 AM ET Company ParticipantsAllan Evans - CEO and ChairmanAustin Bohlig - VP and Equity ResearchBrian Hoff - CFOChristine Petraglia - Founder and CEOJonathan Siegmann - Managing Director, Equity ResearchJosh Sullivan - Managing Director, Equity ResearchConference Call ParticipantsBarry Sine - Senior Equity AnalystMatthew Galinko - SVP, Senior Equity Research AnalystOperatorGreetings, welcome to Unusual Machines fourth quarter and fiscal ...
ACCO(ACCO) - 2025 Q4 - Earnings Call Transcript
2026-03-09 13:32
ACCO Brands (NYSE:ACCO) Q4 2025 Earnings call March 09, 2026 08:30 AM ET Company ParticipantsChris McGinnis - Senior Director of Investor RelationsJagannath Bobji - Senior Vice President, Global Planning and Financial Analysis, and TreasurerTom Tedford - President and CEOConference Call ParticipantsGreg Burns - Research AnalystJoe Gomes - Senior Research AnalystKevin Steinke - Equity Research AnalystOperatorHello, everyone, thank you for joining us today for the ACCO Brands Q4 and 2025 year-end earnings con ...
ACCO(ACCO) - 2025 Q4 - Earnings Call Transcript
2026-03-09 13:32
Financial Data and Key Metrics Changes - Full year 2025 sales and adjusted EPS were in line with the company's outlook, with reported sales in Q4 decreasing by 4% and comparable sales down by 8% [4][11] - Gross profit for Q4 was $144 million, a decrease of 7%, with a margin rate of 33.6%, down 110 basis points due to lower volumes and unfavorable product mix [11][12] - Adjusted operating income for Q4 was $60 million, with a margin rate of 14%, down 30 basis points [12] Business Line Data and Key Metrics Changes - In the Americas segment, comparable sales declined by 5%, but adjusted operating income increased modestly to $43 million, with a margin rate improving by 110 basis points to 17.7% [12][13] - The international segment saw comparable sales decline by 12%, impacted by soft demand in Europe, although growth was noted in Australia [13] - The EPOS acquisition is expected to contribute approximately $80 million in revenue in 2026, with anticipated annual cost synergies of $15 million [14][41] Market Data and Key Metrics Changes - The Americas segment showed improved revenue trends sequentially, particularly in technology accessories, while the international segment faced challenges from EMEA [7][8] - Brazil's 2025 results were lower than expected due to adverse product mix and market trade down, prompting a repositioning of product offerings [9] - The company expects a better year in 2026, with EPS and cash flow anticipated to improve [10] Company Strategy and Development Direction - The company is focusing on the growing technology peripherals market, with the EPOS acquisition broadening its portfolio to represent approximately 25% of projected revenues [4][5] - A multi-year cost reduction program has delivered $35 million in savings in 2025, with a target of $100 million by the end of 2026 [7][10] - The company is committed to operational excellence and cost management to drive revenue growth and improve profits [10][50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategy and ability to navigate external challenges, anticipating revenue growth driven by the EPOS acquisition and improved demand [10][50] - The company expects reported sales for 2026 to be flat to up 3%, with adjusted EPS projected between $0.84 and $0.89 [15] - Management highlighted the importance of maintaining expense discipline while managing gross margin impacts from product mix [10][43] Other Important Information - The company returned $42 million to shareholders in 2025 through dividends and share repurchases [13] - The consolidated leverage ratio at year-end was 4.1 times, with approximately $292 million available for borrowing [14] Q&A Session Summary Question: Can you provide more details on the EPOS acquisition? - The EPOS addressable market is estimated at $1.7 billion, with EPOS holding about 5% market share, indicating significant growth potential [22] Question: What is the outlook for the back-to-school market? - The company anticipates a return to normal ordering patterns, with strong early orders indicating solid performance for the back-to-school season [24] Question: Can you discuss revenue synergies from the EPOS acquisition? - The complementary nature of EPOS and Kensington is expected to create growth synergies, leveraging a broader market presence [30] Question: What are the expectations for gross margin and SG&A expenses in 2026? - Modest gross margin expansion is anticipated due to operational improvements and planned price increases, while SG&A expenses may increase slightly due to incentive payouts [43][44]
Unusual Machines(UMAC) - 2025 Q4 - Earnings Call Transcript
2026-03-09 13:32
Unusual Machines (NYSEAM:UMAC) Q4 2025 Earnings call March 09, 2026 08:30 AM ET Company ParticipantsAllan Evans - CEO and ChairmanAustin Bohlig - VP and Equity ResearchBrian Hoff - CFOChristine Petraglia - Founder and CEOJonathan Siegmann - Managing Director, Equity ResearchJosh Sullivan - Managing Director, Equity ResearchConference Call ParticipantsBarry Sine - Senior Equity AnalystMatthew Galinko - SVP, Senior Equity Research AnalystOperatorGreetings, welcome to Unusual Machines Q4 and FY 2025 financial ...